Cohort study
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease
- Retrospective cohort study
- nationwide
- medico-administrative data
- propensity score matching (sensitivity)
Authors' conclusion
In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease.
Study context
- Population
- Patients undergoing endovascular revascularization (≥1 balloon and/or stent) for lower limb PAD, French National Healthcare System, Oct 2011–Dec 2019analysed
- Participants
- 259,137 patients
- Exposure
- PCD vs no PCD for lower limb endovascular revascularization
- PCDn = 20,083
- Outcome
- All-cause mortality
- Follow-up
- Until December 31, 2021; median 4.1 years (Q1-Q3: 2.3-6.4 years)
Main finding
As reported in the abstract
median follow-up 4.1 years
Hazard ratio
0.86
95% CI 0.84–0.89
P < 0.001
Events by group
PCD
5,385
events
Control
109,844
events
PCD vs Control
HR 0.86 (95% CI 0.84–0.89); P < 0.001
Observational data: associations, not effects.
Original publication
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease. J Am Coll Cardiol. Published 25 March 2024. doi:10.1016/j.jacc.2024.02.003
Summarised from the published abstract; every number is checked against it